Choosing Chemotherapy Drugs for Triple-Negative Breast Cancer

Chemotherapy drug options for triple-negative breast cancer?

Hello Doctor, my mother was diagnosed with triple-negative breast cancer last December, approximately 2.4 cm in size.
The lymph node biopsy did not show any cancer cells because the tumor is located too close to the nipple.
Therefore, it was decided to start with chemotherapy before surgery, hoping to avoid a mastectomy, as my mother is very afraid of having her breast removed.
I researched extensively online and found some foreign websites suggesting that administering carboplatin could lead to better pathological responses.
Some patients also mentioned that for stage III triple-negative breast cancer, carboplatin combined with paclitaxel resulted in no visible cancer cells at the end of treatment.
This news was very encouraging, so during the last outpatient visit before chemotherapy, I asked the doctor if carboplatin could be included.
The doctor mentioned that carboplatin is still considered experimental and is usually not used for breast cancer.
Additionally, there was a suggestion for a more intensive chemotherapy regimen, changing the administration of the red drug (likely referring to a specific chemotherapy agent) from every three weeks to every two weeks.
However, considering my mother's age (she is 55 this year), the doctor ultimately decided to proceed with the standard regimen of the red drug plus another agent (likely referring to a specific chemotherapy drug) every three weeks for a total of four cycles, followed by paclitaxel every three weeks for another four cycles.

After the first chemotherapy session, my mother returned for a follow-up appointment a week later.
The side effects were particularly noticeable for two to three days, with significant nausea, but after that, her appetite improved.
During that visit, her white blood cell count was 3900, and the doctor said her condition was quite ideal since she seemed to be doing well.
This made me want to discuss with the doctor the possibility of adding carboplatin to the paclitaxel regimen moving forward.
I found online that some doctors have recommended carboplatin for stage II triple-negative patients.

Doctor, is carboplatin really still considered experimental? If so, why are many patients receiving it? Moreover, if it has shown good results, why wouldn't my mother's outpatient doctor consider allowing her to receive it? If my mother continues to do well during her red drug chemotherapy, would it be appropriate for me to discuss the possibility of adding carboplatin with her attending physician? Would that be considered impolite? Given that triple-negative breast cancer is known to be quite aggressive, I truly hope for a good pathological response and a favorable prognosis.

Clare, 20~29 year old female. Ask Date: 2017/01/23

Dr. Lai Yicheng reply Oncology

Dear Ms.
Clare,
Thank you for your letter.
I appreciate your concern for your mother; you are a caring daughter.
Regarding the choice of chemotherapy drugs for triple-negative breast cancer that you mentioned, there are some discrepancies with your mother's attending physician's recommendations.
As a third-party physician, I believe it is important to respect your mother's attending physician's decisions, as the chemotherapy drugs chosen for triple-negative breast cancer are standard treatment options.
Wishing you a happy New Year and your mother a speedy recovery.
Sincerely,
Dr.
Lai Yi-Cheng
Department of Radiation Oncology
Changhua Hospital

Reply Date: 2017/01/23

More Info

When it comes to choosing chemotherapy drugs for triple-negative breast cancer (TNBC), especially in the context of your mother's situation, there are several important factors to consider. Triple-negative breast cancer is known for its aggressive nature and lack of targeted therapies, which makes the choice of chemotherapy particularly crucial.

Firstly, it’s important to understand that the standard treatment for TNBC typically involves a combination of chemotherapy agents. Common regimens include anthracyclines (like doxorubicin) and taxanes (like paclitaxel). In your mother's case, the regimen of "小紅莓" (likely referring to a combination of doxorubicin and cyclophosphamide) followed by "歐洲紫杉醇" (paclitaxel) is a well-established approach. This combination has been shown to be effective in many patients with TNBC.

Regarding the use of carboplatin, it is indeed gaining traction in the treatment of TNBC, particularly for patients with a higher risk of recurrence or those with residual disease after initial chemotherapy. Carboplatin can enhance the effectiveness of chemotherapy regimens, especially in patients with BRCA mutations or those who exhibit a high degree of sensitivity to platinum-based drugs. However, its use is often considered on a case-by-case basis, and it may not be the first-line treatment due to potential side effects and the need for careful monitoring.

Your concern about whether carboplatin is still considered "experimental" is understandable. While it is not the standard of care for all TNBC patients, many oncologists are increasingly incorporating it into treatment plans based on emerging evidence from clinical trials. The decision to use carboplatin often depends on the individual patient's health status, the specific characteristics of the tumor, and the oncologist's clinical judgment.

If your mother is tolerating her current chemotherapy regimen well, it is certainly reasonable to discuss the possibility of adding carboplatin with her oncologist. Open communication with the healthcare team is crucial, and expressing your concerns and desires for the best possible treatment is not impolite. Oncologists appreciate when patients and their families are engaged in the treatment process, as it can lead to better outcomes and satisfaction with care.

It’s also worth noting that the response to chemotherapy can vary significantly among patients. While some may experience a complete pathological response (no detectable cancer cells post-treatment), others may not respond as favorably. This variability is part of what makes managing TNBC challenging.

In summary, while carboplatin is not universally used for all TNBC patients, it is increasingly recognized for its potential benefits, particularly in specific contexts. Engaging in a discussion with your mother's oncologist about the possibility of incorporating carboplatin into her treatment plan is a proactive step. It’s essential to weigh the potential benefits against the risks and to consider your mother's overall health and preferences in this decision-making process. Remember, the goal is to achieve the best possible outcome while managing side effects and maintaining quality of life.

Similar Q&A

Understanding Breast Cancer Treatment Options: Chemotherapy vs. Hormonal Therapy

Hello, doctor. I am 32 years old and have stage II breast cancer. I have undergone a lumpectomy on my left breast. The tumor analysis shows: hormone receptor positive, HER2 negative, and Ki67 at 30%. I would like to know if I definitely need to undergo chemotherapy, or if I can b...

Dr. Lai Yicheng reply Oncology
Dear Ms. Vicky, Thank you for your inquiry. Here is my response: 1. Due to the incomplete information you provided, we can only determine that targeted therapy is not required (HER2 negative / Ki67 50%). This is insufficient to ascertain the need for chemotherapy. - Chemother...

Understanding Triple-Negative Breast Cancer: Risks, Treatments, and Prognosis

Hello Doctor, I would like to ask you a question regarding my mother, who is currently 61 years old. She was recently diagnosed with breast cancer (Luminal B type, grade 2) and has just undergone a partial mastectomy and sentinel lymph node biopsy (4 nodes), with no lymph node me...

Dr. Chen Sirong reply Oncology
Hello, 1. I would like to ask the doctor if the risk of recurrence for my mother is high. Using this algorithm, IHC4 = 32 > 30 indicates high risk, with ER = 90, PR = 90, Her2 = 1, and Ki67 = 30 for calculating the IHC4 score. 2. Since the doctor recommends both chemotherap...

Managing Recurrence: Treatment Options for Breast Cancer Patients

Dear Dr. Wu, I apologize for continually bothering you. I have completed my surgery, and 19 lymph nodes were removed, with 17 of them being infected. Currently, my doctor is no longer considering the use of Vinorelbine (he believes it is ineffective) and has suggested using Erib...

Dr. Wu Jingtang reply Breast and Thyroid
Dear Miss Len: 1. Are you planning to pursue aggressive treatment? ---> You should be encouraged! You can rest assured that if chemotherapy becomes intolerable, your physician will pause and make adjustments! 2. After a period of chemotherapy, is it necessary to perform a PE...

Post-Surgery Treatment Considerations for HER2-Positive Breast Cancer Patients

1. The patient has stage I breast cancer (Estrogen receptor: negative / Progesterone receptor: negative / HER2: positive / Ki-67: 60%). The postoperative treatment recommendation is to undergo six cycles of chemotherapy combined with targeted therapy using the following three med...

Dr. Chen Jiaming reply Surgery
If there are concerns regarding the treatment in a clinical situation, it is advisable to discuss them with the attending physician, as online consultation information is insufficient to determine the appropriateness of treatment. The imaging reports prior to chemotherapy and the...